S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
The gold catalyst we've waited for (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
The gold catalyst we've waited for (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
The gold catalyst we've waited for (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
The gold catalyst we've waited for (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:ALLR

Allarity Therapeutics (ALLR) Stock Forecast, Price & News

$0.26
0.00 (0.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.25
▼
$0.27
50-Day Range
$0.26
▼
$3.96
52-Week Range
$0.25
▼
$118.30
Volume
1.22 million shs
Average Volume
2.06 million shs
Market Capitalization
$5.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Allarity Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Allarity Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($30.58) to ($19.82) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.12 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ALLR stock logo

About Allarity Therapeutics (NASDAQ:ALLR) Stock

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLR Stock News Headlines

May 30, 2023 | finance.yahoo.com
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
May 13, 2023 | americanbankingnews.com
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update
June 1, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
April 27, 2023 | finance.yahoo.com
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023
April 20, 2023 | marketwatch.com
Allarity Therapeutics Shares Tumble on Public Offering >ALLR
April 19, 2023 | finance.yahoo.com
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
April 19, 2023 | investorplace.com
Why Is Allarity Therapeutics (ALLR) Stock Down 22% Today?
April 18, 2023 | markets.businessinsider.com
Allarity Soars In Morning Trade
June 1, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
April 17, 2023 | finanznachrichten.de
Allarity Therapeutics, Inc.: This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial
April 17, 2023 | finance.yahoo.com
ALLR: Clinical Update
April 17, 2023 | finance.yahoo.com
This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial
April 16, 2023 | americanbankingnews.com
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Decreases By 70.0%
April 11, 2023 | finance.yahoo.com
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
April 2, 2023 | benzinga.com
Should You Sell Allarity Therapeutics Inc (ALLR) Stock Thursday Morning?
March 31, 2023 | finance.yahoo.com
ALLR: March Clinical Update
March 28, 2023 | finanznachrichten.de
Allarity Therapeutics, Inc.: Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
March 28, 2023 | msn.com
Allarity stock dips amid enrollment woes pushing cancer trials data to year end
March 28, 2023 | finance.yahoo.com
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
March 24, 2023 | finanznachrichten.de
Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Reverse Stock Split of Common Stock
March 24, 2023 | finance.yahoo.com
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
March 20, 2023 | msn.com
Why Allarity Therapeutics Shares Are Soaring
March 20, 2023 | finance.yahoo.com
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
February 23, 2023 | uk.finance.yahoo.com
Allarity Therapeutics, Inc. (ALLR)
February 8, 2023 | finance.yahoo.com
6 F-Rated Penny Stocks Not Worth Your Dime
January 26, 2023 | seekingalpha.com
ALLR Allarity Therapeutics, Inc.
January 23, 2023 | msn.com
Why Is Allarity Therapeutics (ALLR) Stock 72% Up Today?
See More Headlines
Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLR Company Calendar

Today
5/31/2023
Next Earnings (Estimated)
10/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLR
CUSIP
N/A
CIK
1860657
Web
www.allarity.com
Phone
401-426-4664
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,480,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,053.89%
Return on Assets
-95.20%

Debt

Debt-to-Equity Ratio
0.73
Current Ratio
0.26
Quick Ratio
0.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
$2.61 per share
Price / Cash Flow
0.10
Book Value
($0.16) per share
Price / Book
-1.63

Miscellaneous

Outstanding Shares
19,140,000
Free Float
19,049,000
Market Cap
$4.99 million
Optionable
Not Optionable
Beta
-0.42

Key Executives

  • Mr. James G. Cullem J.D. (Age 54)
    Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director
    Comp: $356.85k
  • Dr. Marie Foegh DrSc (Age 79)
    M.D., Chief Medical Officer
    Comp: $424.08k
  • Mr. Peter Buhl Jensen Adj Professor (Age 68)
    M.D., M.D., Ph.D., Ph.D., Co-Founder
  • Dr. Steen Meier Knudsen Ph.D. (Age 62)
    Founder & Chief Scientific Officer
  • Mr. Thomas H. Jensen (Age 45)
    Founder, Sr. VP of Investor Relations & Director
  • Mr. Claus Frisenberg Pedersen (Age 51)
    Chief Commercial Officer
  • Ms. Joan Brown (Age 70)
    Interim CFO & Director of Financial Reporting
  • Ms. Annie Rasmussen (Age 66)
    Chief of Clinical Operations

Key Competitors

View All Competitors













ALLR Stock - Frequently Asked Questions

Should I buy or sell Allarity Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allarity Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLR, but not buy additional shares or sell existing shares.
View ALLR analyst ratings or view top-rated stocks.

How have ALLR shares performed in 2023?

Allarity Therapeutics' stock was trading at $10.2830 at the beginning of 2023. Since then, ALLR stock has decreased by 97.5% and is now trading at $0.2607.
View the best growth stocks for 2023 here.

Are investors shorting Allarity Therapeutics?

Allarity Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 470,800 shares, an increase of 180.4% from the April 30th total of 167,900 shares. Based on an average daily volume of 3,040,000 shares, the short-interest ratio is currently 0.2 days.
View Allarity Therapeutics' Short Interest.

When is Allarity Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 6th 2023.
View our ALLR earnings forecast.

When did Allarity Therapeutics' stock split?

Allarity Therapeutics shares reverse split on Monday, March 27th 2023. The 1-35 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Allarity Therapeutics' stock symbol?

Allarity Therapeutics trades on the NASDAQ under the ticker symbol "ALLR."

How do I buy shares of Allarity Therapeutics?

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allarity Therapeutics' stock price today?

One share of ALLR stock can currently be purchased for approximately $0.26.

How much money does Allarity Therapeutics make?

Allarity Therapeutics (NASDAQ:ALLR) has a market capitalization of $4.99 million.

How can I contact Allarity Therapeutics?

The official website for the company is www.allarity.com. The company can be reached via phone at 401-426-4664 or via email at investorrelations@allarity.com.

This page (NASDAQ:ALLR) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -